Photo via Daily Mail

New 'Viagra for the brain' pill slows clinical decline in Alzheimer's patients by a third

Read the original at Daily Mail ↗
Cite

Wooller, S. (2026, November 16). New 'Viagra for the brain' pill slows clinical decline in Alzheimer's patients by a third. Daily Mail. https://www.dailymail.com/news/article-16297465/New-Viagra-brain-pill-slows-clinical-decline-Alzheimers-patients-third.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

Dated from the outlet's own feed. Check the original for its byline.

Daily Mail · collected 2026-11-16 · by Shaun Wooller

Quick Summary

A South Korean pharmaceutical company, AriBio, has developed a new once-daily pill called AR1001 that slows clinical decline in Alzheimer's patients by 31% compared to a placebo, according to a major phase III trial presented at the Clinical Trials on Alzheimer's Disease conference. The trial involved 1,535 participants across 13 countries and showed that the drug, which works similarly to Viagra by blocking the PDE5 enzyme, could be a more cost-effective alternative to existing treatments that require infusion or injection.
Written by AI on 2026-11-18, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

A new once-daily pill called AR1001, developed by South Korean pharmaceutical firm AriBio, has shown significant promise in treating Alzheimer's disease. Results from a phase III trial presented at the Clinical Trials on Alzheimer's Disease conference in Boston indicate that the drug slows clinical decline by 31% compared to a placebo, equivalent to a delay of 3.5 months after one year. This is the first oral treatment to target the underlying cause of Alzheimer's, unlike existing therapies like lecanemab and donanemab, which require infusion or injection. Dr. David Greeley, a leading Alzheimer's researcher, noted that this alternative could significantly reduce costs and provide a more accessible option for patients who dislike needles or have difficulty accessing clinics.

Written for “New Alzheimer's Treatment Pill” on 2026-11-18, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Story

New Alzheimer's Treatment Pill
Health · 1 article(s) covering the same event.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
36
sentences that state something as happening or true
Uncertain
11%
4 of 36 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
70/100
Daily Mail's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-18 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Daily Mail · 11752 article(s) · 24 correction(s) detected
Running correction rate · 24 correction(s)

Who wrote this

Shaun Wooller
31 article(s) here · 1 carrying a prediction
Having an alternative in tablet form could significantly lower the cost and provide an attractive option to people who dislike needles.
The National Paediatric Early Warning System (Pews) already exists for inpatients, but NHS England said this is the first time it will be used in emergency departments.
Former health secretary Jeremy Hunt said it is 'deeply troubling' that the inquiry may have overlooked the dangers of normal birth ideology because AI was not asked to look for it.
- For confidential advice, call Alzheimer's Society's Dementia Support Line on 0333 150 3456 - Alzheimer's Society's symptoms checker can help spot the signs of dementia - READ MORE: How to spot if someone you love has warning signs of dementia Hundreds of Alzheimer's patients will be given ADHD drugs as part of a world–leading trial that could halve the time it takes to test treatments.
Exercise Cygnus, a pandemic preparedness exercise conducted in October 2016, said more work was needed to ensure there would be enough surge capacity in care homes in the event of a pandemic but this had not been completed by the time the outbreak hit.
Dangerous overcrowding, corridor care and unrelenting demand will create a 'perfect storm' - and current government plans 'won't cut it', the Royal College of Emergency Medicine said.
The Department of Health and Social Care and NHS England told the NHS Pay Review Body that it could not afford to pay more without 'difficult trade–offs', which may involve cutting services or longer waits for care.
Hospital and ambulance staff are required to log events that have harmed a patient or could have done.
We are currently with a generation who are convinced, and rightly so, that they will not have the opportunities that their parents had.'
The Department of Health and Social Care (DHSC) said it will strengthen legislation in a bid to improve standards and curb over-diagnoses.
Also by Shaun Wooller
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 31 articles by Shaun Wooller →

Topics

AR1001 AriBio Dementia Carers Together donanemab lecanemab

Subjects

Alzheimer's Society ORG · 3× AriBio ORG · 2× Dementia Carers Together ORG · 2× Mail Force ORG · 2× Boston GPE · 1× NHS ORG · 1× South Korean NORP · 1× United States GPE · 1× the Daily Mail's ORG · 1× the United Kingdom GPE · 1×

Narrative

Dr David Greeley, a leading clinical researcher in Alzheimer's drug development at Northwest Neurological, in the United States, said: 'As a practicing neurologist and clinical investigator for over thirty years - as well as an investigator for AriBio since Phase 2 - I see
framing: assertive · carried by 1 article(s) · first seen 2026-11-18
Having an alternative in tablet form could significantly lower the cost and provide an attractive option to people who dislike needles.

Claims (36 extracted, 4 hedged)

- Dementia Carers Together is an appeal run by Mail Force in association with Alzheimer's Society, delivering vital support to the UK's unpaid dementia carers - To donate, visit the Dementia Carers Together fundraising page asserted
Together → run → page
A new once-a-day pill that acts like 'Viagra for the brain' has been shown to slow clinical decline in Alzheimer's patients by a third. asserted
that → act → third
The blockbuster therapy delayed progression of the disease by the equivalent of 3.5 months after just one year in a major phase III trial. asserted
therapy → delay → trial
Participants given the drug, known as AR1001 and made by South Korean pharmaceutical firm AriBio, performed 31 per cent better in an assessment of memory, thinking and everyday functioning than those given a placebo. asserted
Participants → give → placebo
Results presented at the Clinical Trials on Alzheimer's Disease conference in Boston, United States, this evening suggest it is the first oral treatment to successfully target an underlying cause of the disease, rather than simply tackle symptoms. asserted
it → present → symptoms
Other disease-modifying therapies, such as lecanemab and donanemab, have to be given by infusion in a clinic or by injection and have not been approved for use on the NHS because of the high cost of administering them. asserted
therapies → modify → them
Having an alternative in tablet form could significantly lower the cost and provide an attractive option to people who dislike needles. uncertain
who → have → needles
The new drug's active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, which is found in Viagra and used to treat erectile dysfunction. asserted
which → belong → dysfunction
They both work to block an enzyme called PDE5, which in turn relaxes blood vessels and increases blood flow. asserted
which → work → flow
The new drug's active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, which is found in Viagra and used to treat erectile dysfunction. asserted
which → belong → dysfunction
AR1001 is thought to have a number of beneficial effects in the brain, including lowering inflammation, increasing blood flow and protecting nerve cells. asserted
AR1001 → think → cells
The global trial involved 1,535 people with Alzheimer's from 230 sites in 13 countries, including the United Kingdom. asserted
trial → involve → Kingdom
Researchers found the 31 per cent benefit among patients who were not taking any other dementia medications, known as the 'monotherapy' group. asserted
who → find → group
A lesser benefit of 7 per cent was found among those who took AR1001 alongside other dementia drugs but this was not considered statistically significant. asserted
this → find → drugs
AR1001 operates differently to existing disease-modifying treatments lecanemab and donanemab, which help remove amyloid plaque from the brain. asserted
which → operate → brain
Most side effects reported in the trial were mild or moderate, with the most common being diarrhoea, falls and dizziness. asserted
common → report → trial
Some 69 per cent of people receiving AR1001 reported side effects, compared to 66.4 per cent receiving the placebo. asserted
cent → receive → placebo
AriBio also looked at markers of Alzheimer's disease in cerebrospinal fluid and found lower levels of ptau217, which is tested to identify the presence of both amyloid and tau - hallmarks of Alzheimer's in the brain. asserted
which → look → brain
The findings come as the Daily Mail's Dementia Carers Together Appeal is raising money for new six-week courses for friends and relatives of people living with the disease. asserted
Appeal → come → disease
Delivered in partnership with Alzheimer's Society and the Mail Force charity, the sessions will give carers vital support and information about their rights and the services available to them. asserted
sessions → deliver → them
They will allow attendees to meet others in a similar situation and help to address the loneliness, exhaustion and overwhelming responsibilities many face following a loved one's diagnosis. asserted
many → allow → diagnosis
Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, said: 'These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms. ' uncertain
that → say → causes
Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third. asserted
drug → slow → third
However, results were not apparent in people taking other drugs for Alzheimer's symptoms, so this needs further investigation. asserted
this → take → investigation
AR1001 works differently from other disease-modifying treatments we've seen so far and, as a once-a-day tablet, could offer a simpler way for people to receive treatment. uncertain
people → work → treatment
Reported side effects were mostly mild to moderate in severity. asserted
effects → report → severity
This drug is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer's disease. asserted
it → develop → disease
People should not take Viagra to try to treat Alzheimer's. asserted
People → take → Alzheimer
It's important to note AR1001 is not yet available to the public and will need to be assessed and approved by UK regulatory bodies before it could be offered in the UK. uncertain
it → note → UK
'Research is making huge progress and will beat dementia – and as more potential treatments emerge, it's more important than ever that people get an early and accurate dementia diagnosis so they can benefit from them. asserted
they → make → them
We look forward to seeing the full results from this trial and how this drug progresses.' asserted
drug → look → trial
Dr David Greeley, a leading clinical researcher in Alzheimer's drug development at Northwest Neurological, in the United States, said: 'As a practicing neurologist and clinical investigator for over thirty years - as well as an investigator for AriBio since Phase 2 - I see asserted
I → lead → Phase
how urgently patients and families need treatments for Alzheimer's disease. asserted
patients → need → disease
The findings in the pre-specified Monotherapy population of the AriBio study recently released are very encouraging and support the premise of a once-daily oral approach to this devastating disease. asserted
findings → release → disease
If approved, this oral drug would broaden patients' options. asserted
drug → approve → options
Further evaluation is needed, but our goal is meaningful treatment that not only helps patients but that can be realistically afforded, received and sustained.' asserted
that → need → patients
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support